Regulatory context

Not approved, and in regulatory limbo

No FDA-approved drug product contains dihexa. In the United States it entered a specific limbo in 2026: dihexa acetate came off the 503A compounding category 2 list after the nomination behind it was withdrawn, with an advisory-committee consultation to follow, which is not the same as approval.

This unit maps the status this course could verify, explains what the 503A change does and does not mean, covers anti-doping, and compares dihexa honestly against the approved options it is discussed alongside. Status statements are timestamped to 2026.